S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
S&P 500   3,137.46 (+0.05%)
DOW   27,920.99 (+0.04%)
QQQ   204.32 (+0.12%)
AAPL   269.22 (+0.86%)
FB   200.60 (-0.37%)
MSFT   151.39 (+0.02%)
NVDA   214.53 (+1.11%)
MU   47.84 (+2.97%)
BABA   201.44 (+1.36%)
TSLA   349.18 (+2.84%)
F   9.08 (+0.67%)
NFLX   295.09 (-2.45%)
GILD   67.01 (+0.10%)
DIS   146.47 (+0.18%)
Log in

NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

$3.94
+0.17 (+4.52 %)
(As of 12/10/2019 02:12 PM ET)
Today's Range
$3.77
Now: $3.94
$3.94
50-Day Range
$3.00
MA: $3.37
$3.88
52-Week Range
$1.87
Now: $3.94
$28.25
Volume41,106 shs
Average Volume35,558 shs
Market Capitalization$39.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.90 million
Book Value$4.64 per share

Profitability

Net Income$-21,280,000.00

Miscellaneous

Employees23
Market Cap$39.74 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.


Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) announced its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.05. View Acer Therapeutics' Earnings History.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Acer Therapeutics.

What price target have analysts set for ACER?

5 brokers have issued twelve-month price targets for Acer Therapeutics' shares. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 687.8% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

What is the consensus analysts' recommendation for Acer Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

Has Acer Therapeutics been receiving favorable news coverage?

News coverage about ACER stock has been trending somewhat positive on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acer Therapeutics earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Acer Therapeutics.

Are investors shorting Acer Therapeutics?

Acer Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totalling 607,500 shares, a decrease of 8.6% from the October 31st total of 664,400 shares. Based on an average daily trading volume, of 83,600 shares, the days-to-cover ratio is currently 7.3 days. Currently, 12.5% of the shares of the stock are short sold. View Acer Therapeutics' Current Options Chain.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the folowing people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
  • Mr. Harry S. Palmin, COO & CFO (Age 49)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
  • Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
  • Ms. Jeannie Kim, VP of Corp. Devel.

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (1.49%), Barclays PLC (0.95%) and Millennium Management LLC (0.15%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.

Which major investors are buying Acer Therapeutics stock?

ACER stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Barclays PLC and Millennium Management LLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $3.94.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $39.74 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is http://www.acertx.com/.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]


MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel